

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3033.1000-008		APPLICATION NO. 10/050,611	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		APPLICANT Darrell H. Carney		RECEIVED MAY 24 2002	
April 2, 2002 (Use several sheets if necessary)		FILING DATE January 16, 2002		GROUP 1653	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS
AA	5,352,664	10/04/94	Carney et al.	514	13
AB	5,500,412	03/19/96	Carney et al.	514	13
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS
AL					
AM					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	Hendel, R.C., et al., "Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion," <i>Journal of The American Heart Association</i> , 101(2):118-121, (2000).				
AS	Aoki, M., et al., "Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets," <i>Gene Therapy</i> , 7(5):417-427, (2000).				
AT	Pecher, P., and Schumacher, B.A., "Angiogenesis is Ischemic Human Myocardium: Clinical Results After 3 Years," <i>The Annals of Thoracic Surgery</i> , 69(5):1414-1419, (2000).				
AU	Kawasuji, M., et al., "Therapeutic Angiogenesis With Intramyocardial Administration of Basic Fibroblast Growth Factor," <i>The Annals of Thoracic Surgery</i> , 69(4):1155-1161, (2000).				
AV	Rosengart, T.K., et al., "Six-Month Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA," <i>Annals of Surgery</i> , 230(4):466-472, (1999).				
AW	Laham, R.J., et al., "Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution," <i>Drug Metabolism and Disposition</i> , 27(7):821-826, (1999).				
AX	Sellke, F.W., et al., "Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results," <i>The Annals of Thoracic Surgery</i> , 65(6):1540-1544, (1998).				
AY	Folkman, J., "Angiogenic Therapy of the Human Heart," <i>Journal of The American Heart Association</i> , 97(7):628-629, (1998).				
AZ	McKenna, C.J., et al., "Selective ET _A Receptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model," <i>Journal of The American Heart Association</i> , 97(25):2551-2556, (1998).				
EXAMINER		DATE CONSIDERED			
[Signature]		3/1/04			

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3033.1000-008		APPLICATION NO. 10/050,611		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 2, 2002 (Use several sheets if necessary)		APPLICANT Darrell H. Carney		RECEIVED MAY 24 2002 TECH CENTER 1600/2900		
		FILING DATE January 16, 2002				GROUP 1653
U.S. PATENT DOCUMENTS						
EXAM INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
CITE MAY 23 2002 JUL 23 2002 PATENT & TRADEMARK						RECEIVED
						JUN 20 2002
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
AR2	FRIMERMAN, A., et al., "Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model," <i>Journal of The American Heart Association</i> , 99(5):697-703, (1999).					
AS2	VOISARD, R., et al., "High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis," <i>Coronary Artery Disease</i> , 8(3/4):189-201, (1997).					
AT2	NADIR, M., et al., "Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine," <i>Coronary Artery Disease</i> , 7(11):851-861, (1996).					
AU2	MUNRO, E., et al., "Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis," <i>European Journal of Clinical Investigation</i> , 24(11):766-772, (1994).					
AV2	CHEN, S.J., et al., "Mithramycin Inhibits Myointimal Proliferation After Balloon Injury of the Rat Carotid Artery In Vivo," <i>Circulation</i> , 90(5):2468-2473, (1994).					
AW2	SHI, Y., et al., "Downregulation of c-myc Expression by Antisense Oligonucleotides Inhibits Proliferation of Human Smooth Muscle Cells," <i>Circulation</i> , 88(3):1190-1195, (1993).					
AX2	SPEIR, E., and EPSTEIN, S.E., "Inhibition of Smooth Muscle Cell Proliferation by an Antisense Oligodeoxynucleotide Targeting the Messenger RNA Encoding Proliferating Cell Nuclear Antigen," <i>Circulation</i> , 86(2):538-547, (1992).					
AY2	STIERNBERG, J., et al., "The Role of Thrombin and Thrombin Receptor Activating Peptide (TRAP-508) in Initiation of Tissue Repair," <i>Thrombosis and Haemostasis</i> , 70(1):158-162, (1995).					
EXAMINER <i>[Signature]</i>		DATE CONSIDERED 3/1/04				

P10-1449 REPRODUCED		ATTORNEY DOCKET NO. 3033.1000-008		APPLICATION NO. 10/050,611	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION April 2, 2002 (Use several sheets if necessary)		APPLICANT Darrell H. Carney		RECEIVED MAY 24 2002	
		FILING DATE January 16, 2002			
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS FILING DATE IF APPROPRIATE
					RECEIVED
					JUN 20 2002
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
me	A22	Carney, D.H., et al., "Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides," <i>J. Clin. Invest.</i> , 89:1469-1477, (1992).			
	AR3	Carney, D.H., et al., "Role of High-Affinity Thrombin Receptors in Postclotting Cellular Effects of Thrombin," <i>Seminars in Thrombosis and Hemostasis</i> , 18(1):91-102, (1992).			
	AS3	Stiernberg, J., et al., "Acceleration of full-thickness wound healing in normal rats by the synthetic thrombin peptide, TP508," <i>Wound Repair and Regeneration</i> , 8(3):204-215, (2000).			
	AT3	Glenn, K.C., et al., "Synthetic Peptides Bind to High-Affinity Thrombin Receptors and Modulate Thrombin Mitogenesis," <i>Peptide Research</i> , 1(2):65-73, (1988).			
	AU3	Sower, L.E., et al., "Thrombin Peptide, TP508, Induces Differential Gene Expression in Fibroblasts through a Nonproteolytic Activation Pathway," <i>Experimental Cell Research</i> , 247:422-431, (1999).			
me	AV3	Carney, D.H., "Postclotting Cellular Effects of Thrombin Mediated by Interaction with High-Affinity Thrombin Receptors," <i>Thrombin: Structure and Function</i> , Chapter 10, pp. 351-396, (1992).			
EXAMINER		DATE CONSIDERED			
[Signature]		3/1/04			

ATTORNEY DOCKET NO.
3033.1000-008APPLICATION NO.
10/050,611SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION IN AN APPLICATIONAPPLICANT
Darrell H. Carney

July 23, 2002

FILING DATE

July 16, 2002

GROUP
1653

(Use several sheets if necessary)

PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
							RECEIVED
							JUL 21 2002
							TECH CENTER 1000/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL		WO 88/03151	05-MAY-88	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

3/1/04

[illegible]

APPLICATION NO.
10/050,611

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION IN AN APPLICATION**

APPLICANT
Darrell H. Carney

JUN 24 2013

June 12, 2003

(Use several sheets if necessary)

~~FILING DATE~~
January 16, 2002

CONFIRMATION-NO.	GROUP
6599	1653

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER

DATE CONSIDERED

3/1/64

